400 related articles for article (PubMed ID: 26542681)
1. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.
Yeddula N; Xia Y; Ke E; Beumer J; Verma IM
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6476-85. PubMed ID: 26542681
[TBL] [Abstract][Full Text] [Related]
2. EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells.
Chen YH; Lv H; Shen N; Wang XM; Tang S; Xiong B; Ding J; Geng MY; Huang M
Acta Pharmacol Sin; 2020 Feb; 41(2):270-277. PubMed ID: 31316177
[TBL] [Abstract][Full Text] [Related]
3. Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene.
Sukka-Ganesh B; Mohammed KA; Kaye F; Goldberg EP; Nasreen N
BMC Cancer; 2012 Jul; 12():309. PubMed ID: 22824143
[TBL] [Abstract][Full Text] [Related]
4. Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas.
McCleland ML; Adler AS; Deming L; Cosino E; Lee L; Blackwood EM; Solon M; Tao J; Li L; Shames D; Jackson E; Forrest WF; Firestein R
Clin Cancer Res; 2013 Feb; 19(4):773-84. PubMed ID: 23224736
[TBL] [Abstract][Full Text] [Related]
5. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.
Ji Z; Mei FC; Xie J; Cheng X
J Biol Chem; 2007 May; 282(19):14048-55. PubMed ID: 17353198
[TBL] [Abstract][Full Text] [Related]
7. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
8. Noncanonical GLI1 signaling promotes stemness features and in vivo growth in lung adenocarcinoma.
Po A; Silvano M; Miele E; Capalbo C; Eramo A; Salvati V; Todaro M; Besharat ZM; Catanzaro G; Cucchi D; Coni S; Di Marcotullio L; Canettieri G; Vacca A; Stassi G; De Smaele E; Tartaglia M; Screpanti I; De Maria R; Ferretti E
Oncogene; 2017 Aug; 36(32):4641-4652. PubMed ID: 28368412
[TBL] [Abstract][Full Text] [Related]
9. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M
Cancer Res; 2012 Jun; 72(12):3048-59. PubMed ID: 22511580
[TBL] [Abstract][Full Text] [Related]
10. Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.
Dos Santos EO; Carneiro-Lobo TC; Aoki MN; Levantini E; Bassères DS
Mol Cancer; 2016 Feb; 15():12. PubMed ID: 26842935
[TBL] [Abstract][Full Text] [Related]
11. Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas.
Li J; Sordella R; Powers S
Sci Rep; 2016 Jun; 6():27891. PubMed ID: 27301828
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Mutant
Zhou X; Padanad MS; Evers BM; Smith B; Novaresi N; Suresh S; Richardson JA; Stein E; Zhu J; Hammer RE; O'Donnell KA
Mol Cancer Res; 2019 Feb; 17(2):594-603. PubMed ID: 30409919
[TBL] [Abstract][Full Text] [Related]
13. In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer.
Grzeskowiak CL; Kundu ST; Mo X; Ivanov AA; Zagorodna O; Lu H; Chapple RH; Tsang YH; Moreno D; Mosqueda M; Eterovic K; Fradette JJ; Ahmad S; Chen F; Chong Z; Chen K; Creighton CJ; Fu H; Mills GB; Gibbons DL; Scott KL
Nat Commun; 2018 Jul; 9(1):2732. PubMed ID: 30013058
[TBL] [Abstract][Full Text] [Related]
14. Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma.
Wang Y; Hou N; Cheng X; Zhang J; Tan X; Zhang C; Tang Y; Teng Y; Yang X
Int J Biol Sci; 2017; 13(5):652-659. PubMed ID: 28539837
[TBL] [Abstract][Full Text] [Related]
15. Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression.
Cicchini M; Buza EL; Sagal KM; Gudiel AA; Durham AC; Feldser DM
Cell Rep; 2017 Feb; 18(8):1958-1969. PubMed ID: 28228261
[TBL] [Abstract][Full Text] [Related]
16. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
[TBL] [Abstract][Full Text] [Related]
17. Thyroid transcription factor-1-regulated microRNA-532-5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells.
Griesing S; Kajino T; Tai MC; Liu Z; Nakatochi M; Shimada Y; Suzuki M; Takahashi T
Cancer Sci; 2017 Jul; 108(7):1394-1404. PubMed ID: 28474808
[TBL] [Abstract][Full Text] [Related]
18. Ophiopogonin B suppresses the metastasis and angiogenesis of A549 cells in vitro and in vivo by inhibiting the EphA2/Akt signaling pathway.
Chen M; Hu C; Guo Y; Jiang R; Jiang H; Zhou Y; Fu H; Wu M; Zhang X
Oncol Rep; 2018 Sep; 40(3):1339-1347. PubMed ID: 29956803
[TBL] [Abstract][Full Text] [Related]
19. Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.
Yurugi H; Marini F; Weber C; David K; Zhao Q; Binder H; Désaubry L; Rajalingam K
Oncogene; 2017 Aug; 36(33):4778-4789. PubMed ID: 28414306
[TBL] [Abstract][Full Text] [Related]
20. MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance.
Gao X; Chen G; Gao C; Zhang DH; Kuan SF; Stabile LP; Liu G; Hu J
Mol Oncol; 2017 Jun; 11(6):628-639. PubMed ID: 28306189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]